Salute e Benessere

e.l.f. Beauty Scores with U.K.'s Accrington Stanley Women Football Club

With women leadership as a core inspiration for the players, e.l.f. will lean in and raise the stakes by bringing inspiration and empowerment to the team, working with England International Lioness Izzy Christiansen. In addition to supporting the international tour, the partnership includes Christiansen-hosted training sessions for the club, bringing energy to the supporters with interactive activities at games, e.l.f supported kit and a new team mascot, Sticky, who takes the form of e.l.f. holy…
PR Newswire
21/05/2024

MARS ANNOUNCES PARTNERSHIP WITH TRIPADVISOR, CONNECTING TODAY'S PET PARENTS WITH…

"At Mars, we're dedicated to becoming the most digitally enabled, pet parent-centric organization, which means collaborating with innovators like Tripadvisor to transform the pet parent experience," says Natalia Ball, Global Chief Growth Officer of Mars Pet Nutrition. "This partnership cements our commitment to supporting pet parent communities, using our unmatched expertise, knowledge and relationship with over 400 million pets and their pet parents who purchase our products…
PR Newswire
21/05/2024

Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03…

Dr. Reddy's gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)Alvotech will be responsible for development and manufacture of the product HYDERABAD, INDIA & REYKJAVIK, ICELAND— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of...
Nasdaq GlobeNewswire
21/05/2024

EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian…

COPENHAGEN, Denmark, May 21, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced that Laurence de Moerlooze will leave her position as Executive Vice President and Chief Medical Officer in the Company to pursue new opportunities. She will continue to support Bavarian Nordic until the end of May 2024. The Company will initiate a search process to identify the next Chief Medical Officer.Paul Chaplin, President & CEO of Bavarian Nordic, said: “On behalf of everyone at Bavarian Nordic,...
Nasdaq GlobeNewswire
21/05/2024

Etiometry Awarded Frost & Sullivan's 2024 North American Enabling Technology…

Etiometry's software solutions deliver actionable insights to healthcare professionals. The company offers the first and only clinical decision support technology with explicit Food and Drug Administration (FDA) clearance for use at the bedside for patient monitoring. This FDA-approved platform offers essential data visualization and analytics that support clinical decisions in ICU environments. These innovations dramatically enhance patient outcomes and increase hospital throughput and…
PR Newswire
21/05/2024

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; May 21, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from May 13, 2024 to May 17, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...
Nasdaq GlobeNewswire
21/05/2024

Biopharma Leaders Shape the Future of Drug Development at Veeva R&D and Quality…

As one of the largest gatherings of biopharma leaders in Europe, Veeva R&D and Quality Summit will bring together over 1,000 industry professionals to share learnings across more than 100 sessions. Bayer and Jazz Pharmaceuticals will join Rik Van Mol, senior vice president of Veeva Development Cloud, and Avril England, general manager of Veeva Vault, for the opening keynote to explore the future of development for new medicines and therapies. As one of the largest gatherings of biopharma...
PR Newswire
21/05/2024

Dragonfly Therapeutics, Inc. Announces Clinical Collaboration to Evaluate…

"Merck, a trusted leader in drug development, has been a wonderful collaborator with Dragonfly since we signed our first collaboration agreement in 2018," said Bill Haney, co-founder and CEO of Dragonfly Therapeutics. "We are pleased to enter into this agreement with Merck for our ongoing, investigational Phase 1 trial of DF9001. In preclinical models, DF9001 engages multiple immune effector cells to drive anti-tumor activity and induces PD-L1 expression in tumor cells…
PR Newswire
21/05/2024

Clario partners with Emsere to extend ophthalmic medical imaging capabilities…

Central to this partnership is Emsere's global presence, which complements Clario's commitment to delivering tailored solutions that address the challenges of each trial phase and modality. This relationship is significant because it will cater to sites that lack the necessary equipment to meet study protocols. Customers of Clario and Emsere can now benefit from a unified approach, combining Clario's clinical trial expertise and manufacturer-agnostic ophthalmic software with Emsere's services…
PR Newswire
21/05/2024

BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy…

MAINZ, Germany, May 21, 2024– BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company's diversified immuno-oncology pipeline at the American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, Illinois, from May 31 to June 4, 2024. Moreover, in support of the Company's ongoing CAR-T cell and individualized mRNA programs, BioNTech will also present epidemiological and real-world data from two...
Nasdaq GlobeNewswire
21/05/2024

Next Generation Drug Conjugates Market Worth USD 7.94 Billion to 2031 -…

Request for Free Sample Pages: https://www.insightaceanalytic.com/report/next-generation-drug-conjugates-market/2482 Request for Free Sample Pages: https://www.insightaceanalytic.com/report/next-generation-drug-conjugates-market/2482 Next Generation Drug Conjugates Market Report Scope: Growth of the next-generation drug conjugates market is driven by several factors, such as the recent accelerated approvals of various next-generation drug conjugates and the keen interest shown by...
PR Newswire
21/05/2024

Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024

Sanbexin®, the only Class 1 innovative drug approved worldwide since 2015, has been shown to reduce brain cell damage and dysfunction caused by ischemia and hypoxia in stroke patients. Its significance lies in its ability to combat the devastating effects of stroke, which is the second most common fatal disease globally and the first most common inChina. The high recurrence rate, disability rate, and mortality rate associated with stroke place a heavy burden on society. InChina,...
PR Newswire
21/05/2024

Oncology Events in Poland Solidify Collaboration with NCCN

"We are honored to contribute in part to the ambitious Polish National Oncological Strategy," said Dr. Denlinger. "Since the beginning of our collaboration, we have been able to jointly adapt NCCN Guidelines for six cancer types into regional adaptations tailored specifically to the needs and realities of people with cancer in the Polish region. It has been a privilege to work alongside so many committed and knowledgeable Polish and American leaders on this shared mission for…
PR Newswire
21/05/2024

Pheon Therapeutics announces $120m Series B financing to fund development of its…

Cyrus Mozayeni MD, Chief Executive Officer of Pheon, said: "This raise is a critical step as we transition into a clinical-stage company. The proceeds will fund a robust clinical development pathway for our first three ADC assets, which are based on an exceptional novel target. We are excited to be working on these promising candidates and look forward to sharing their potential therapeutic benefits with patients." Cyrus MozayeniMD, Chief Executive Officer of Pheon, said:"This…
PR Newswire
21/05/2024

Furniture Village: The 5 Bedroom Colours Taking Over Instagram Right Now

1. Pink bedrooms – 85k Instagram hashtags - the most popular colour schemePink makes a statement. The hashtag #pinkbedroom has a huge 85 thousand posts – the top bedroom colour on Instagram. Users are likely searching for pink bedrooms as the colour is known to give a calming effect that evokes warmth and love. Furniture Village said "Pink is the perfect colour for a romantic bedroom," and #romanticbedroom has 12.8 thousand posts too. #farmhousebedroom has 105 thousand posts, which…
PR Newswire
21/05/2024

Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI…

Sanofi, Formation Bio and OpenAI announce first-in-class AI collaborationParis, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of...
Nasdaq GlobeNewswire
21/05/2024

Hansa Biopharma to present data at 2024 American Transplant Congress annual…

Imlifidase has conditional marketing approval in Europe under the trade name IDEFIRIX® for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. The Company is conducting an open label, randomized controlled Phase 3 trial in the US in kidney transplantation and plans to submit a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) in 2025. The molecule is also being studied as…
PR Newswire
21/05/2024

Idorsia announces changes to Idorsia Executive Committee and Board of Directors

Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of DirectorsMathieu Simon to stand for re-election to the Board – taking on the role of Vice-Chairman and Lead Independent DirectorAndré C. Muller, current CFO of Idorsia, to take over the role of CEO as of June 13, 2024Allschwil, Switzerland – May 21, 2024Idorsia Ltd (SIX: IDIA) today announced changes to the Idorsia Executive Committee (IEC) and will...
Nasdaq GlobeNewswire
21/05/2024

Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

Saint-Herblain (France), May 21, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (CSO) and Executive Committee member, effective June 3, 2024.Valneva decided to complement its Executive Team with an accomplished R&D leader to oversee the further evolution of the Company´s R&D portfolio. Specifically, Dr. Schuitemaker will focus on accelerating...
Nasdaq GlobeNewswire
21/05/2024

FDA grants Breakthrough Therapy Designation to Roche's inavolisib for advanced…

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting 1 Approximately 40% of people with HR-positive breast cancer have aPIK3CAmutation and often face poorer prognosis and resistance to endocrine treatment 2,3This is the 29th Breakthrough Therapy Designation for Roche's oncology portfolio, a testament to our...
Nasdaq GlobeNewswire
21/05/2024

Idorsia announces financial results for the first quarter 2024 – advancing the…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlights Viatris collaboration : Global research and development collaboration, focused on the development and commercialization of two innovative compounds, selatogrel and cenerimod.Commercial highlights QUVIVIQ™ (daridorexant):Total net sales of CHF 10 million in Q1 2024. QUVIVIQ in...
Nasdaq GlobeNewswire
21/05/2024

Idorsia announces financial results for the full year of 2023 – Adapting the…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year of 2023. Business highlights Sale of Idorsia Asia-Pacific operations (excluding China):Sold to Nxera Pharma (previously known as Sosei Heptares) for a total consideration of CHF 400 million in July 2023. Cost reduction initiative:Delivering a 50% reduction in fixed cost at Swiss headquarters fully effective in early 2024...
Nasdaq GlobeNewswire
21/05/2024

ILJIN SNT Co., Ltd. Calls for Board Restructure at Aurinia Pharmaceuticals

ILJIN SNT Co., Ltd. and its affiliates (collectively, "ILJIN") is a long-term holder of more than 5% of Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") and has been supportive of the Company's mission since 2010 when we invested in the predecessor company, Isotechnika. As one of the largest and longest-standing shareholders, we have had the privilege of supporting the Company through its drug development efforts and subsequent FDA approval of LUPKYNIS. We…
PR Newswire
21/05/2024

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available…

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira®REYKJAVIK, ICELAND & PARSIPPANY, NJ — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult...
Nasdaq GlobeNewswire
21/05/2024
Altri  Comunicati